Ra Capital Management, L.P. Adverum Biotechnologies, Inc. Transaction History

Ra Capital Management, L.P.

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	BUY	$0.81 - $1.34 $1.4 Million - $2.31 Million	1,726,019 New	1,726,019 $2.07 Million
Q2 2021 Aug 16, 2021	SELL	$3.36 - $10.56 $31.5 Million - $98.9 Million	-9,365,833 Closed	0 $0
Q1 2021 May 17, 2021	SELL	$9.26 - $14.36 $1.26 Million - $1.96 Million	-136,550 Reduced 1.44%	9,365,833 $92.3 Million
Q4 2020 Feb 16, 2021	BUY	$9.84 - $14.26 $900,586 - $1.31 Million	91,523 Added 0.97%	9,502,383 $103 Million
Q3 2020 Nov 16, 2020	BUY	$10.3 - $21.64 $16.6 Million - $34.8 Million	1,609,219 Added 20.63%	9,410,860 $96.9 Million
Q2 2020 Aug 14, 2020	BUY	$8.53 - $25.64 $4.51 Million - $13.6 Million	528,927 Added 7.27%	7,801,641 $163 Million
Q1 2020 May 15, 2020	BUY	$7.98 - $16.32 $58 Million - $119 Million	7,272,714 New	7,272,714 $71.1 Million

524K

Ticker ADVM
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 99,333,600
Market Cap $471M
Description
Adverum Biotechnologies, Inc., a clinical-stage gene therapy company, develops gene therapy product candidates to treat ocular and rare diseases. Its lead product candidate is ADVM-022, a single intravitreal injection gene therapy candidate used for the treatment of patients with chronic retinal, including wet age-related macular degeneration an...

Get notified when there are updates to the investment portfolio of Ra Capital Management, L.P., based on Form 13F filings with the SEC.

Stay updated on Ra Capital Management, L.P. with notifications on news.